Effect of UDP-glucuronosyltransferase 1A8 polymorphism on raloxifene glucuronidation

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 2, 2013, Pages 199-205

  Kokawa, Yuki ^a   Kishi, Naoki ^a   Jinno, Hideto ^b   Tanaka Kagawa, Toshiko ^b   Narimatsu, Shizuo ^a   Hanioka, Nobumitsu ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Genetic polymorphism; Glucuronidation; Raloxifene; UDP glucuronosyltransferase 1A8 (UGT1A8)

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A8; MYCOPHENOLIC ACID; RALOXIFENE; RECOMBINANT ENZYME;

ALLOSTERISM; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; GENETIC POLYMORPHISM; GLUCURONIDATION; HUMAN; MICHAELIS MENTEN KINETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SF9 CELL; WILD TYPE;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; ESTROGEN ANTAGONISTS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; POLYMORPHISM, GENETIC; RALOXIFENE; SF9 CELLS; SPODOPTERA;

EID: 84875400577     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.03.001     Document Type: Article

References (36)

1. O. Bernard, and C. Guillemette The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants Drug Metab. Dispos. 32 2004 775 778
2. O. Bernard, J. Tojcic, K. Journault, L. Perusse, and C. Guillemette Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid Drug Metab. Dispos. 34 2006 1539 1545
3. T.B. Bevers Raloxifene and the prevention of breast cancer Expert. Opin. Pharmacotherapy 7 2006 2301 2307
4. R.K. DeLisle, J. Otten, and S. Rhodes In silico modeling of P450 substrates, inhibitors, activators, and inducers Comb. Chem. High Throughput Screen. 14 2011 396 416
5. J.A. Dodge, C.W. Lugar, S. Cho, L.L. Short, M. Sato, N.N. Yang, L.A. Spangle, M.J. Martin, D.L. Phillips, A.L. Glasebrook, J.J. Osborne, C.A. Frolik, and H.U. Bryant Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity J. Steroid Biochem. Mol. Biol. 61 1997 97 106
6. R. Fujiwara, M. Nakajima, T. Yamamoto, H. Nagao, and T. Yokoi In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9 Drug Metab. Pharmacokinet. 24 2009 235 244
7. A. Ghosal, N. Hapangama, Y. Yuan, J. Achanfuo-Yeboah, R. Iannucci, S. Chowdhury, K. Alton, J.E. Patrick, and S. Zbaida Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil) Drug Metab. Dispos. 32 2004 267 371
8. N. Hanioka, Y. Takeda, H. Jinno, T. Tanaka-Kagawa, S. Naito, A. Koeda, T. Shimizu, M. Nomura, and S. Narimatsu Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A6 enzymes Chem. Biol. Interact. 164 2006 136 145
9. N. Hanioka, N. Tanabe, H. Jinno, T. Tanaka-Kagawa, K. Nagaoka, S. Naito, A. Koeda, and S. Narimatsu Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes Life Sci. 87 2010 261 268
10. H. Hansdóttir Raloxifene for older women: a review of the literature Clin. Int. Aging. 3 2008 45 50
11. M. Heringa Review on raloxifene: profile of a selective estrogen receptor modulator Int. J. Clin. Pharmacol. Ther. 41 2003 331 345
12. D. Hochner-Celnikier Pharmacokinetics of raloxifene and its clinical application Eur. J. Obstet. Gynecol. Reprod. Biol. 85 1999 23 29
13. Y.H. Huang, A. Galijatovic, N. Nguyen, D. Geske, D. Beaton, J. Green, M. Green, W.H. Peters, and R.H. Tukey Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3 Pharmacogenetics 12 2002 287 297
14. T. Izukawa, M. Nakajima, R. Fujiwara, H. Yamanaka, T. Fukami, M. Takamiya, Y. Aoki, S. Ikushiro, T. Sakaki, and T. Yokoi Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers Drug Metab. Dispos. 37 2009 1759 1768
15. E.J. Jeong, H. Lin, and M. Hu Disposition mechanisms of raloxifene in the human intestinal Caco-2 model J. Pharmacol. Exp. Ther. 310 2004 376 385
16. E.J. Jeong, Y. Liu, H. Lin, and M. Hu Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10 Drug Metab. Dispos. 33 2005 785 794
17. T. Kaku, K. Ogura, T. Nishiyama, T. Ohnuma, K. Muro, and A. Hiratsuka Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4 Biochem. Pharmacol. 67 2004 2093 2102
18. D.C. Kemp, P.W. Fan, and J.C. Stevens Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance Drug Metab. Dispos. 30 2002 694 700
19. T.K. Kiang, M.H. Ensom, and T.K. Chang UDP-glucuronosyltransferases and clinical drug-drug interactions Pharmacol. Ther. 106 2005 97 132
20. C.W. Locuson, and T.S. Tracy Comparative modelling of the human UDP-glucuronosyltransferases: insights into structure and mechanism Xenobiotica 37 2007 155 168
21. P.I. Mackenzie Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid Ther. Drug Monit. 22 2000 10 13
22. P.I. Mackenzie, P.A. Gregory, D.A. Gardner-Stephen, R.H. Lewinsky, B.R. Jorgensen, T. Nishiyama, W. Xie, and A. Radominska-Pandya Regulation of UDP glucuronosyltransferase genes Curr. Drug Metab. 4 2003 249 257
23. P.I. Mackenzie, K.W. Bock, B. Burchell, C. Guillemette, S. Ikushiro, T. Iyanagi, J.O. Miners, I.S. Owens, and D.W. Nebert Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily Pharmacogenet. Genomics 15 2005 677 685
24. J. Magdalou, S. Fournel-Gigleux, and M. Ouzzine Insights on membrane topology and structure/function of UDP-glucuronosyltransferases Drug Metab. Rev. 42 2010 159 166
25. M.J. Miley, A.K. Zielinska, J.E. Keenan, S.M. Bratton, A. Radominska-Pandya, and M.R. Redinbo Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7 J. Mol. Biol. 369 2007 498 511
26. T. Mizuma Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10 Int. J. Pharm. 378 2009 140 141
27. M.D. Moen, and G.M. Keating Raloxifene: a review of its use in the prevention of invasive breast cancer Drugs 68 2008 2059 2083
28. K.C. Morello, G.T. Wurz, and M.W. DeGregorio Pharmacokinetics of selective estrogen receptor modulators Clin. Pharmacokinet. 42 2003 361 372
29. S. Ohno, and S. Nakajin Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction Drug Metab. Dispos. 37 2009 32 40
30. A. Radominska-Pandya, P.J. Czernik, J.M. Little, E. Battaglia, and P.I. Mackenzie Structural and functional studies of UDP-glucuronosyltransferases Drug Metab. Rev. 31 1999 817 899
31. K.R. Snyder, N. Sparano, and J.M. Malinowski Raloxifene hydrochloride Am. J. Health Syst. Pharm. 57 2000 1669 1675
32. T. Trdan Lušin, A. Mrhar, B. Stieger, G.A. Kullak-Ublick, J. Marc, B. Ostanek, A. Zavratnik, A. Kristl, K. Berginc, K. Delić, and J. Trontelj Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment Trans. Res. 160 2012 298 308
33. R.H. Tukey, and C.P. Strassburg Human UDP-glucuronosyltransferases: metabolism, expression, and disease Annu. Rev. Pharmacol. Toxicol. 40 2000 581 616
34. J.F. Wang, and K.C. Chou Molecular modeling of cytochrome P450 and drug metabolism Curr. Drug Metab. 11 2010 342 346
35. i/AUC) ratios Drug Metab. Dispos. 32 2004 1201 1208
36. L. Živanović, A. Protić, M. Zečević, B. Jocić, and M. Kostić Multicriteria optimization methodology in development of HPLC separation of mycophenolic acid and mycophenolic acid glucuronide in human urine and plasma J. Pharm. Biomed. Anal. 50 2009 640 648